Benitec has announced an exclusive licensing deal with Stanford University. Under the license, Benitec receives exclusive rights to use the Minicircle DNA technology pioneered at Stanford University for all RNAi therapeutic uses, with sub-licensing rights.
In the field of RNAi therapeutics, effective delivery continues to be the primary hurdle to overcome. Minicircles, developed by Mark A. Kay, M.D., Ph.D., Professor of Pediatrics and Genetics at Stanford University and Strategic Consultant to Benitec, provides a significant advance over current RNAi non-viral systems and expands the repertoire of non-viral delivery methods available to researchers undertaking therapeutic programs.
“With this new technology, we have demonstrated therapeutic levels of transgene product in animal models for up to 10 months, with no toxicity from this non-integrating vector” stated Dr. Kay. “We designed a unique plasmid to allow for easy purification and large-scale production of Minicircles, making this a feasible vector for clinical use.”
Minicircles result in gene expression up to 500 times greater than that seen with traditional plasmid DNA (Chen, et al. Mol Ther 2001; 3:403-410) and were created from the discovery in the Kay laboratory that bacterial sequences present in normal plasmid DNA result in significant down-regulation of gene expression in animal models.